Background: The 21-gene assay (the Oncotype DX Breast Recurrence Score test) is a validated multigene assay which produces the Recurrence Score result (RS) to inform decisions on the use of adjuvant chemotherapy in human epidermal growth factor receptor 2-negative (HER2-), hormone receptor positive (HR+) early invasive breast cancer. A model-based economic evaluation estimated the cost-effectiveness of the 21-gene assay against the use of clinical risk tools alone based on the latest evidence from prospective studies.
Methods: The proportion of patients assigned to chemotherapy conditional on their RS result was obtained from retrospective data from the Clalit registry. The probability of distant recurrence with endocrine and chemo-endocrine therapy conditional on RS result was obtained from TAILORx and NSABP B-20 trials. The cost-effectiveness of the 21-gene assay compared to using clinical risk tools alone was estimated in terms of cost per quality-adjusted life-year (QALY) over a lifetime horizon.
Results: The 21-gene assay was more effective (0.17 more quality-adjusted life years) at a lower cost (-£519) over a lifetime compared to clinical risk alone. The model results were sensitive to assumptions around the magnitude of benefit of chemotherapy in the high RS result subgroup. Other assumptions underpinning the model, such as the proportion of patients assigned to chemotherapy in the low and mid-range RS result subgroups and long-term distant recurrence probabilities, had a smaller impact on the results.
Conclusion: The analysis showed that the cost-effectiveness of the 21-gene assay is sensitive to assumptions for chemotherapy sparing for patients with RS 0-25 whose outcomes with endocrine therapy are no worse compared to chemotherapy-assigned patients, and a chemotherapy benefit in the RS 26-100 group. Future studies need to incorporate a wider set of tumour profiling tests other than the 21-gene assay to allow a direct comparison of their cost-effectiveness.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505370 | PMC |
| http://dx.doi.org/10.2147/CEOR.S360049 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unveiling the Mechanisms of a Remission in Major Depressive Disorder (MDD)-like Syndrome: The Role of Hippocampal Palmitoyltransferase Expression and Stress Susceptibility.
Biomolecules
January 2025
Research and Education Resource Center, Peoples Friendship University of Russia (RUDN University), 117198 Moscow, Russia.
Post-translational modifications of proteins via palmitoylation, a thioester linkage of a 16-carbon fatty acid to a cysteine residue, reversibly increases their affinity for cholesterol-rich lipid rafts in membranes, changing their function. Little is known about how altered palmitoylation affects function at the systemic level and contributes to CNS pathology. However, recent studies suggested a role for the downregulation of palmitoyl acetyltransferase (DHHC) 21 gene expression in the development of Major Depressive Disorder (MDD)-like syndrome.
View Article and Find Full Text PDFEvidence for Bxy-npr-21 on controlling juveniles' growth and modulating male sexual arousal: from molecules to behaviors.
Pest Manag Sci
January 2025
College of Forestry and Biotechnology, Zhejiang A & F University, Hangzhou, 311300, China.
Background: Bursaphelenchus xylophilus is considered a quarantine plant nematode species, that causes major damage to pine ecosystems globally. However, there are few reports on the identification and function of the sex pheromone receptors involved in mating. The function of Bxy-npr-21 as a potential sex pheromone receptor gene was verified from molecules to behaviors in this study.
View Article and Find Full Text PDFPrognostic Performance of the Next-Generation Sequencing-Based Multigene Assay in Early Breast Cancer Patients Treated According to the 21-Gene Assay Results.
Cancer Res Treat
December 2024
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Purpose: Multigene assays guide treatment decisions in early-stage hormone receptor-positive breast cancer. OncoFREE, a next-generation sequencing assay using 179 genes, was developed for this purpose. This study aimed to evaluate the concordance between the Oncotype DX (ODX) Recurrence Score (RS) and the OncoFREE Decision Index (DI) and to compare their performance.
View Article and Find Full Text PDFChallenges and barriers for the adoption of personalized medicine in Europe: the case of Oncotype DX Breast Recurrence Score test.
Diagnosis (Berl)
December 2024
Sarah Cannon Research Institute, Nashville, TN, USA.
Article Synopsis
- Personalized medicine in oncology has great potential, but its adoption in Europe is hindered by various challenges, as seen with the Oncotype DX Breast Recurrence Score assay.
- The case study details obstacles faced in integrating this genomic test into European healthcare from 2004 to 2018, including issues with clinical evidence, reimbursement, and regulatory processes.
- Key findings from the TAILORx study suggest that, for certain breast cancer patients, endocrine therapy may suffice without the need for additional adjuvant chemotherapy, highlighting the importance of personalized treatment approaches.
Pathogen class-specific transcriptional responses derived from PBMCs accurately discriminate between fungal, bacterial, and viral infections.
PLoS One
December 2024
Division of Infectious Diseases, Duke University, Durham, North Carolina, United States of America.
Article Synopsis
- Immune responses to acute infections share common elements across different pathogens, which can aid in creating better diagnostics and treatments.
- Analysis of gene expression in white blood cells shows these common patterns, helping to identify the type of infection (viral or bacterial).
- A study identified a 41-gene signature that classifies infections with high accuracy and a smaller 21-gene subset that distinguishes between specific infections, underscoring the potential for developing effective diagnostic tools.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!